These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751 [TBL] [Abstract][Full Text] [Related]
23. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver. Ng CS; Hobbs BP; Wei W; Anderson EF; Herron DH; Yao JC; Chandler AG J Comput Assist Tomogr; 2015; 39(3):373-82. PubMed ID: 25626401 [TBL] [Abstract][Full Text] [Related]
24. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276 [TBL] [Abstract][Full Text] [Related]
25. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report. Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634 [TBL] [Abstract][Full Text] [Related]
26. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243 [TBL] [Abstract][Full Text] [Related]
27. Whole tumour perfusion of peripheral lung carcinoma: evaluation with first-pass CT perfusion imaging at 64-detector row CT. Li Y; Yang ZG; Chen TW; Deng YP; Yu JQ; Li ZL Clin Radiol; 2008 Jun; 63(6):629-35. PubMed ID: 18455553 [TBL] [Abstract][Full Text] [Related]
28. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection. Arai T; Kobayashi A; Fujinaga Y; Yokoyama T; Shimizu A; Motoyama H; Kitagawa N; Notake T; Shirota T; Fukushima K; Masuo H; Kadoya M; Miyagawa S Pancreatology; 2016; 16(3):397-402. PubMed ID: 26850565 [TBL] [Abstract][Full Text] [Related]
29. The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography. Chew C; O'Dwyer PJ Singapore Med J; 2016 Jun; 57(6):334-8. PubMed ID: 27353741 [TBL] [Abstract][Full Text] [Related]
30. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900 [TBL] [Abstract][Full Text] [Related]
31. Computed tomography perfusion analysis of pancreatic carcinoma. Klauss M; Stiller W; Fritz F; Kieser M; Werner J; Kauczor HU; Grenacher L J Comput Assist Tomogr; 2012; 36(2):237-42. PubMed ID: 22446366 [TBL] [Abstract][Full Text] [Related]